Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial

被引：0
|
作者：
Bang, Y.
Kim, Y. W.
Yang, H.
Chung, H. C.
Park, Y.
Lee, K.
Lee, K. H.
Kim, Y. H.
Noh, S.
Ji, J.
Johnston, M.
Sirzen, F.
Noh, S. H.
机构：
[1] Seoul Natl Univ, Coll Med, Seoul, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Goyang, Gyeonggi, South Korea
[3] Seoul Natl Univ Hosp, Dept Surg, Seoul 110744, South Korea
[4] Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Shinchon Dong, South Korea
[5] Chonnam Natl Univ, Sch Med, Dept Surg, Jeollanam Do, South Korea
[6] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Songnam, Gyeonggi Do, South Korea
[7] Yeungnam Univ Hosp, Taegu, South Korea
[8] KyungHee Med Ctr, Seoul, South Korea
[9] Seoul Vet Hosp, Seoul, South Korea
[10] Beijing Canc Hosp, Beijing, Peoples R China
[11] Roche Prod Pty Ltd, Dee Why, Australia
[12] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[13] Yonsei Univ Hlth Syst, Dept Surg, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4002
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial
    Bang, Y.
    Kim, Y. W.
    Yang, H.
    Chung, H. C.
    Park, Y.
    Lee, K.
    Lee, K. H.
    Kim, Y. H.
    Noh, S.
    Ji, J.
    Johnston, M.
    Sirzen, F.
    Noh, S. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Capecitabine and oxaliplatin (XEOLX) in adjuvant gastric cancer
    Bounedjar, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 87 - 87
  • [3] Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    Bang, Yung-Jue
    Kim, Young-Woo
    Yang, Han-Kwang
    Chung, Hyun Cheol
    Park, Young-Kyu
    Lee, Kyung Hee
    Lee, Keun-Wook
    Kim, Yong Ho
    Noh, Sang-Ik
    Cho, Jae Yong
    Mok, Young Jae
    Kim, Yeul Hong
    Ji, Jiafu
    Yeh, Ta-Sen
    Button, Peter
    Sirzen, Florin
    Noh, Sung Hoon
    [J]. LANCET, 2012, 379 (9813): : 315 - 321
  • [4] Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
    Sergio Frustaci
    Angela Buonadonna
    Elisa Turchet
    Giuseppe Corona
    Gianna Tabaro
    GianMaria Miolo
    Elena Torrisi
    Giovanni Lo Re
    Salvatore Tumolo
    Giuseppe Toffoli
    [J]. International Journal of Clinical Oncology, 2013, 18 : 510 - 516
  • [5] Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
    Frustaci, Sergio
    Buonadonna, Angela
    Turchet, Elisa
    Corona, Giuseppe
    Tabaro, Gianna
    Miolo, GianMaria
    Torrisi, Elena
    Lo Re, Giovanni
    Tumolo, Salvatore
    Toffoli, Giuseppe
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 510 - 516
  • [6] Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
    Schmoll, Hans-Joachim
    Tabernero, Josep
    Maroun, Jean
    de Braud, Filippo
    Price, Timothy
    Van Cutsem, Eric
    Hill, Mark
    Hoersch, Silke
    Rittweger, Karen
    Haller, Daniel G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3733 - +
  • [7] Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial
    Tian, Yuan
    Yang, Peigang
    Guo, Honghai
    Liu, Yang
    Zhang, Ze
    Ding, Pingan
    Zheng, Tao
    Deng, Huiyan
    Ma, Wenqian
    Li, Yong
    Fan, Liqiao
    Zhang, Zhidong
    Wang, Dong
    Zhao, Xuefeng
    Tan, Bibo
    Liu, Yu
    Zhao, Qun
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (12) : 4000 - 4008
  • [8] Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
    Guo, Weijian
    Zhu, Xiaodong
    Huang, Mingzhu
    Wang, Yusheng
    Chen, Zhiyu
    Feng, Wanjing
    He, Yifu
    Zhang, Xiaowei
    Liu, Xin
    Wang, Chenchen
    Zhang, Wen
    Ying, Jieer
    Wu, Jun
    Yang, Lei
    Qin, Yanru
    Zhao, Xiaoying
    Li, Wenhua
    Zhang, Zhe
    Qiu, Lixin
    Wang, XiaoFeng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results
    Czito, Brian G.
    Bendell, Johanna C.
    Willett, Christopher G.
    Morse, Michael A.
    Blobe, Gerard C.
    Tyler, Douglas S.
    Thomas, John
    Ludwig, Kirk A.
    Mantyh, Christopher R.
    Ashton, Jill
    Yu, Daohai
    Hurwitz, Herbert I.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (02): : 472 - 478
  • [10] A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)
    Kawabata, R.
    Terazawa, T.
    Matsuyama, J.
    Endo, S.
    Shiraishi, O.
    Fujita, S.
    Akamaru, Y.
    Taniguchi, H.
    Tatsumi, M.
    Gotoh, M.
    Lee, S-W.
    Kurokawa, Y.
    Shimokawa, T.
    Sakai, D.
    Kato, T.
    Fujitani, K.
    Satoh, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 226 - 226
12345